Lusutrombopag

Last updated
Lusutrombopag
Lusutrombopag.svg
Clinical data
Pronunciationloo" soo trom' boe pag
Trade names Mulpleta, Mulpleo
AHFS/Drugs.com Monograph
MedlinePlus a618043
License data
Routes of
administration 		By mouth
ATC code
Legal status
Legal status
  • US: ℞-only
  • EU:Rx-only
  • In general: ℞ (Prescription only)
Identifiers
  • (E)-3-[2,6-Dichloro-4-[[4-[3-[(1S)-1-hexoxyethyl]-2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic acid
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
Formula C29H32Cl2N2O5S
Molar mass 591.54 g·mol−1
3D model (JSmol)
  • CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(/C=C(\C)C(=O)O)c(Cl)c3)n2)c1OC
  • InChI=1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)/b17-13+/t18-/m0/s1 Yes check.svgY
  • Key:NOZIJMHMKORZBA-KJCUYJGMSA-N Yes check.svgY
 X mark.svgNYes check.svgY  (what is this?)

Lusutrombopag, sold under the brand name Mulpleta among others, is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts) such as thrombocytopenia associated with chronic liver disease in patients prior to elective invasive procedures. [1] It is being manufactured in Philadelphia, PA and marketed in Japan by Shionogi. [2] [3] [4] It was approved by the U.S. Food and Drug Administration (FDA) in July 2018, and NICE in January 2020. [5] [6]

It was approved for medical use in the European Union in February 2019. [7]

References

  1. ↑ Shirley M, McCafferty EH, Blair HA (October 2019). "Lusutrombopag: A Review in Thrombocytopenia in Patients with Chronic Liver Disease Prior to a Scheduled Procedure". Drugs. 79 (15): 1689–1695. doi:10.1007/s40265-019-01197-8. PMID   31529283. S2CID   202574131.
  2. ↑ Shionogi Receives Marketing and Manufacturing Approval in Japan for Mulpleta Tablets 3mg for Improvement of Thrombocytopenia, September 28, 2015
  3. ↑ Shionogi Launches Mulpleta Tablets 3mg In Japan for Improvement of Thrombocytopenia
  4. ↑ Lusutrombopag (Mulpleta) for severe thrombocytopenia in patients with chronic liver disease undergoing an elective invasive procedure
  5. ↑ "FDA approves lusutrombopag for thrombocytopenia in adults with chronic liver disease". U.S. Food and Drug Administration (FDA). July 31, 2018.
  6. ↑ "Overview | Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedure | Guidance | NICE". 8 January 2020.
  7. ↑ "Mulpleo EPAR". European Medicines Agency (EMA). 14 March 2019. Retrieved 17 June 2020.


This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.